AstraZeneca Lifts 2022 Guidance After Swing to 3Q Profit, Higher Sales -- Update
2022年11月10日 - 05:38PM
Dow Jones News
By Cecilia Butini
AstraZeneca PLC on Thursday lifted its guidance for the full
year after reporting a swing to net profit and higher sales for the
third quarter of the year, which both beat consensus
expectations.
The Anglo-Swedish pharma major swung to a pretax profit of $922
million from a pretax loss of $2 billion the year prior, when it
took hits from fair-value adjustments to Alexion inventories after
acquiring the company.
After tax, profit was $1.64 billion compared with a loss of
$1.65 billion the year prior. Analysts had expected the company to
post a net profit of $629 million.
Core earnings per share were $1.67, up 55% from the prior-year
figure, beating analysts' expectations of $1.52.
Revenue rose to $11 billion in the quarter from $9.87 billion
the year prior, boosted by growth in all disease areas as well as
from the addition of Alexion Pharmaceuticals, and beating analysts'
expectations of $10.84 billion.
Revenue at the company's oncology segment grew by 24% in the
first nine months of the year while oncology product sales rose
20%.
AstraZeneca reported a decline in revenue for its Covid-19
vaccine, as it had previously foreseen. The shot totaled revenue of
$180 million, down from $1.05 billion in the third quarter of 2021
when the company started selling it at a profit. In general,
revenue in certain markets, such as emerging markets, declined as a
result of lower sales of the vaccine.
Key medicines such as lung-cancer treatment Tagrisso,
liver-cancer treatment Imfinzi and ovarian-cancer drug Lynparza all
showed an uptick in sales in the third quarter, the company
said.
The company raised its outlook on core earnings per share as it
expects the metric to increase by a high-20s to low-30s percentage,
up from a previous outlook of growth in the mid-to-high 20s
percentage.
Total revenue is still expected to increase by a low-20s
percentage as the company had previously forecast.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
November 10, 2022 03:23 ET (08:23 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
過去 株価チャート
から 2 2024 まで 3 2024
Astrazeneca (LSE:AZN)
過去 株価チャート
から 3 2023 まで 3 2024